Biopharmaceutical - Clinical Stage Drug Development
Strategic Profile
Altimmune has received FDA Breakthrough Therapy Designation for its treatment pemvidutide, showing promising results in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). The company is set to enter a Phase 3 trial, aiming for accelerated approval, while analysts predict a substantial upside for the stock.
Cyborg Score Rationale
Altimmune demonstrates strong clinical progress with FDA Breakthrough Therapy designation and promising Phase 2b data for pemvidutide in a large market (MASH, obesity). Analyst consensus shows strong buy ratings with significant upside potential. However, as a clinical-stage company with minimal revenue, it carries execution risk and capital requirements.
Top Insights
FDA Breakthrough Therapy Designation granted for pemvidutide in MASH, enabling accelerated approval pathway
Phase 3 trial enrollment underway following strong 48-week Phase 2b IMPACT trial efficacy and safety data
Analysts rate stock as Strong Buy with average 12-month price target of $16.00 (241% upside)
Dual indication strategy targets MASH, obesity, AUD, and ALD with potential multi-billion dollar market opportunity